

LANCE® Ultra

**ULight™ -labeled Streptavidin**

Product number: TRF0102-R Lot Number: 3258514

---

Product Format: TRF0102-D: 1 nmole (100µL)  
TRF0102-M: 10 nmoles (1mL)  
TRF0102-R: 100 nmoles (10mL)

Manufacturing date: 01/29/2024 Document version: 1

**Product Information**

**Storage Buffer:** 50 mM Tris-HCl (pH 7.4), 0.9% NaCl, 0.1% BSA and 0.05% sodium azide as preservative  
**Molecular Weight:** 60 000  
**Stability:** This product is stable for at least **24 months** from the manufacturing date when stored in its original packaging and the recommended storage conditions.  
**Storage Conditions:** Store at 4°C. Store protected from light.

**Quality Control**

The QC release specifications are based on spectrophotometric analysis of the labeled antibody. We certify that results meet our quality release criteria.

**Labeling Ratio:** 3.1(dye molecule/peptide)  
**Concentration:** 600 µg/mL (10 µM)

**Recommended Assay Conditions**

Src kinase assay: ATP titration

## SUGGESTED METHOD:

(Specific applications might require optimization)

### Reagent Preparation


- Prepare 1X Kinase Buffer: 50 mM Tris-HCl pH 7.5, 1 mM EGTA, 10 mM MgCl<sub>2</sub>, 2 mM DTT and 0.01% Tween-20.
- Prepare a 2X c-Src enzyme solution: dilute the enzyme to a concentration of 2 nM in Kinase Buffer. Keep on ice.
- Prepare a 4X mix of biotin-poly GT: dilute biotin-poly GT to a concentration of 400 nM in Kinase Buffer. Keep on ice.
- Prepare a 4X mix of ATP: dilute ATP to concentrations ranging from 40 nM to 4 mM (serial half-log dilutions) in Kinase Buffer. Keep on ice.
- Prepare 1X Detection Buffer: dilute 0.5 mL of 10X detection buffer with 4.5 mL of H<sub>2</sub>O.
- Prepare a 4X Stop Solution: prepare a 40 mM EDTA solution in 1X Detection Buffer.
- Prepare a 4X Detection Mix: dilute the Eu-W1024-labeled PY20 antibody to 8 nM and *ULight*-Streptavidin to 200 nM in 1X Detection Buffer.

### Protocol

- Pipet 5 µL of 2X c-Src enzyme into a 384-well white OptiPlate™-384 (1 nM final concentration).
- Add 2.5 µL of 4X biotin-poly-GT (100 nM final concentration).
- Add 2.5 µL of 4X ATP mix (10 nM to 1 mM final concentrations).
- Cover plate with TopSeal-A and incubate 90 min at 23°C.
- Add 5 µL of 4X Stop Solution and incubate 5 min at 23°C.
- Add 5 µL of 4X Detection Mix (2 nM Eu-W1024-labeled PY20 antibody and 50 nM *ULight*-Streptavidin final concentrations).
- Cover plate with TopSeal-A and incubate 60 min at 23°C.
- Remove TopSeal-A and read in TR-FRET mode at 665 nm (excitation at 320 or 340 nm).

## Typical Product Data

Src kinase assay using *ULight*-Streptavidin, biotin poly GT and Eu-PY20 anti phosphotyrosine obtained using the EnVision® Multilabel Reader:



### Suggested Materials

- Detection: *ULight*™ - Streptavidin
- Substrate: biotin-poly GT (4:1)
- Antibody: Eu-W1024 anti-phosphotyrosine (PY20)
- Kinase: c-Src

### Supplier

Revvity Inc  
Revvity Inc  
Revvity Inc  
UpState

- Detection Buffer: LANCE<sup>®</sup> Detection Buffer, 10X
- Plate: OptiPlate™-384, white
- TopSeal™-A

Revvity Inc  
Revvity Inc  
Revvity Inc

The information provided in this document is valid for the specified lot number and date of analysis. This information is for reference purposes only and does not constitute a warranty or guarantee of the product's suitability for any specific use. Revvity, Inc., its subsidiaries, and/or affiliates (collectively, "Revvity") do not assume any liability for any errors or damages arising from the use of this document or the product described herein. REVVITY EXPRESSLY DISCLAIMS ALL WARRANTIES, INCLUDING WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, REGARDLESS OF WHETHER ORAL OR WRITTEN, EXPRESS OR IMPLIED, ALLEGEDLY ARISING FROM ANY USAGE OF ANY TRADE OR ANY COURSE OF DEALING, IN CONNECTION WITH THE USE OF INFORMATION CONTAINED HEREIN OR THE PRODUCT ITSELF.

TRF0102-R Rev01

The logo for Revvity, featuring the word "revvity" in a lowercase, sans-serif font.

Revvity, Inc.  
940 Winter Street  
Waltham, MA 02451 USA

(800) 762-4000 [www.revvity.com](http://www.revvity.com)

For a complete listing of our global offices, visit [www.revvity.com](http://www.revvity.com)  
Copyright ©2023, Revvity, Inc. All rights reserved.